Bristol Myers Squibb's Zeposia Launch Trajectories Diverge in Germany and the UK Following Negative NICE Decision; Janssen's Ponvory Could Likewise Stumble, According to Spherix Global Insights

/PRNewswire/ -- Following the May 2020 European Medicines Agency (EMA) approval of Bristol Myers Squibb's Zeposia and the May 2021 approval of Janssen's...

Related Keywords

Germany ,Italy ,United Kingdom ,France ,Spain ,German ,Kristen Henn ,Janssen Ponvory ,Sanofi Aubagio ,Bristol Myers Squibb Zeposia ,Novarti Gilenya ,Roche Ocrevus ,Bristol Myers Squibb ,Novarti Kesimpta ,Merck Kgaa Mavenclad ,National Institute For Health ,European Medicines Agency ,Regulatory Agency ,National Health Service ,Business Development ,Medicines Agency ,National Institute ,Care Excellence ,Spherix Realtime Dynamix ,Multiple Sclerosis ,Realworld Dynamix ,Realtime Dynamix ,Time Dynamix ,World Dynamix ,Global Insights ,Spherix Global Insights ,